# A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

> **NCT01059318** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01059318
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059318, "A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01059318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*